Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Emicizumab

Shire Basingstoke

Shire signs deal to buy NPS for $5.2bn

Firm hopes to boost its presence in rare disease sector

- PMLiVE

Double trial disappointment for Roche

Discontinues Alzheimer’s programme and finds Kadcyla no better than Herceptin in certain breast cancer

Roche - Basel

Roche leads pharma R&D spend for 2013

Top 30 pharma companies spent a total of $112bn on research

- PMLiVE

Roche and Exelixis file melanoma duo in US

Combination of cobimetinib and Zelboraf improved progression-free survival by 9.9 months

- PMLiVE

Roche’s early development head Richard Scheller to retire

Will be replaced by Michael Varney from the company's Genentech business

- PMLiVE

Roche appoints business director in Spain

Promotion for Rosi Vivancos

- PMLiVE

NICE backtracks on Gazyvaro rejection

Roche agrees to patient access scheme to help gain leukaemia recommendation

- PMLiVE

NHS names drugs to be re-evaluated for Cancer Drugs Fund

Will assess cost-effectiveness of drugs including Kadcyla and Avastin

- PMLiVE

SMC fails to recommend Roche’s Perjeta

Says drug is not a cost-effective option in breast cancer

Shire Basingstoke

Shire drawn into Luxembourg tax haven exposé

Firm is one of 340 companies identified in report by ICIJ

Roche - Basel

Roche invests in diagnostics in China

Commits 450m Swiss francs to manufacturing facility

Biogen Idec building

EMA starts review of Biogen Idec’s haemophilia A therapy

Elocta already on the market in the US, Canada and Australia

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links